FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101175123> ?p ?o ?g. }

• W2101175123 endingPage "1942" @default.
• W2101175123 startingPage "1935" @default.
• W2101175123 abstract "Since it was suggested that B cells play a role in the pathogenesis of chronic graft-versus-host disease, rituximab, an anti-CD20 monoclonal antibody targeting B cells, has been shown to be effective in steroid-refractory, chronic graft-versus-host disease. However, most of the data were from small numbers of patients or retrospective analyses. We, therefore, conducted a multicenter phase II study to confirm the efficacy of this treatment strategy that targets B cells.We diagnosed and evaluated chronic graft-versus-host disease according to the National Institute of Health criteria for clinical trials on this condition. The treatment consisted of weekly intravenous infusions of rituximab for 4 weeks followed by monthly rituximab for 4 months. We evaluated the patients' responses and monitored their disease activity until their final visit, which was on day 365. We also assessed the patients' subsequent quality of life and serum levels of B-cell-activating factor of the tumor necrosis factor family.Among 37 patients enrolled (median age, 29 years; range 8-57 years), 32 patients responded to rituximab with 8 complete and 24 partial responses. Twenty-one patients maintained their response for 1 year, so their steroid treatment was discontinued or its dose reduced (21/37, or 56.8%), and their scores representing quality of life were improved although these changes were not statistically significant. The responses were better for clinical manifestations of the skin, oral cavity and musculoskeletal system (response rate, 71.4-100%) than for other organs. However, infectious complications and primary disease relapse accounted for the majority of treatment failure. The pre-treatment serum level of B cell-activating factor of the tumor necrosis factor family was not associated with better treatment outcome (P=0.147).Rituximab could improve clinical responses and quality of life of patients with steroid-refractory chronic graft-versus-host disease, although such patients may need active prophylaxis against infection." @default.
• W2101175123 created "2016-06-24" @default.
• W2101175123 creator A5004166441 @default.
• W2101175123 creator A5008938100 @default.
• W2101175123 creator A5011687418 @default.
• W2101175123 creator A5012187284 @default.
• W2101175123 creator A5014044521 @default.
• W2101175123 creator A5015112169 @default.
• W2101175123 creator A5049891346 @default.
• W2101175123 creator A5060239856 @default.
• W2101175123 creator A5063101533 @default.
• W2101175123 creator A5066039159 @default.
• W2101175123 creator A5068674293 @default.
• W2101175123 creator A5068837815 @default.
• W2101175123 creator A5070313719 @default.
• W2101175123 creator A5073690360 @default.
• W2101175123 creator A5077318648 @default.
• W2101175123 creator A5081839494 @default.
• W2101175123 creator A5082144323 @default.
• W2101175123 creator A5082389619 @default.
• W2101175123 creator A5085429434 @default.
• W2101175123 creator A5087839513 @default.
• W2101175123 date "2010-07-27" @default.
• W2101175123 modified "2023-10-13" @default.
• W2101175123 title "Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study" @default.
• W2101175123 cites W1995326684 @default.
• W2101175123 cites W2011578371 @default.
• W2101175123 cites W2014041834 @default.
• W2101175123 cites W2019419625 @default.
• W2101175123 cites W2023239299 @default.
• W2101175123 cites W2030196077 @default.
• W2101175123 cites W2036872637 @default.
• W2101175123 cites W2039904206 @default.
• W2101175123 cites W2052079772 @default.
• W2101175123 cites W2055216460 @default.
• W2101175123 cites W2055313377 @default.
• W2101175123 cites W2059769534 @default.
• W2101175123 cites W2063803441 @default.
• W2101175123 cites W2064840987 @default.
• W2101175123 cites W2071336127 @default.
• W2101175123 cites W2082600447 @default.
• W2101175123 cites W2104585211 @default.
• W2101175123 cites W2109346271 @default.
• W2101175123 cites W2110395869 @default.
• W2101175123 cites W2123868466 @default.
• W2101175123 cites W2139184776 @default.
• W2101175123 cites W2143436585 @default.
• W2101175123 cites W2157583708 @default.
• W2101175123 cites W2160666689 @default.
• W2101175123 cites W2164945798 @default.
• W2101175123 cites W2328305239 @default.
• W2101175123 cites W2379365975 @default.
• W2101175123 cites W2414946148 @default.
• W2101175123 cites W2618073389 @default.
• W2101175123 cites W614531583 @default.
• W2101175123 doi "https://doi.org/10.3324/haematol.2010.026104" @default.
• W2101175123 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2966917" @default.
• W2101175123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20663943" @default.
• W2101175123 hasPublicationYear "2010" @default.
• W2101175123 type Work @default.
• W2101175123 sameAs 2101175123 @default.
• W2101175123 citedByCount "90" @default.
• W2101175123 countsByYear W21011751232012 @default.
• W2101175123 countsByYear W21011751232013 @default.
• W2101175123 countsByYear W21011751232014 @default.
• W2101175123 countsByYear W21011751232015 @default.
• W2101175123 countsByYear W21011751232016 @default.
• W2101175123 countsByYear W21011751232017 @default.
• W2101175123 countsByYear W21011751232018 @default.
• W2101175123 countsByYear W21011751232019 @default.
• W2101175123 countsByYear W21011751232020 @default.
• W2101175123 countsByYear W21011751232021 @default.
• W2101175123 countsByYear W21011751232022 @default.
• W2101175123 countsByYear W21011751232023 @default.
• W2101175123 crossrefType "journal-article" @default.
• W2101175123 hasAuthorship W2101175123A5004166441 @default.
• W2101175123 hasAuthorship W2101175123A5008938100 @default.
• W2101175123 hasAuthorship W2101175123A5011687418 @default.
• W2101175123 hasAuthorship W2101175123A5012187284 @default.
• W2101175123 hasAuthorship W2101175123A5014044521 @default.
• W2101175123 hasAuthorship W2101175123A5015112169 @default.
• W2101175123 hasAuthorship W2101175123A5049891346 @default.
• W2101175123 hasAuthorship W2101175123A5060239856 @default.
• W2101175123 hasAuthorship W2101175123A5063101533 @default.
• W2101175123 hasAuthorship W2101175123A5066039159 @default.
• W2101175123 hasAuthorship W2101175123A5068674293 @default.
• W2101175123 hasAuthorship W2101175123A5068837815 @default.
• W2101175123 hasAuthorship W2101175123A5070313719 @default.
• W2101175123 hasAuthorship W2101175123A5073690360 @default.
• W2101175123 hasAuthorship W2101175123A5077318648 @default.
• W2101175123 hasAuthorship W2101175123A5081839494 @default.
• W2101175123 hasAuthorship W2101175123A5082144323 @default.
• W2101175123 hasAuthorship W2101175123A5082389619 @default.
• W2101175123 hasAuthorship W2101175123A5085429434 @default.
• W2101175123 hasAuthorship W2101175123A5087839513 @default.
• W2101175123 hasBestOaLocation W21011751231 @default.
• W2101175123 hasConcept C121332964 @default.
• W2101175123 hasConcept C126322002 @default.

• next